Nature: CLIP1-LTK, a new target for non-small cell lung cancer was discovered, and loratinib works well

According to global statistics , among all types of cancer, lung cancer has the highest mortality rate, accounting for 19% of cancer-related deaths and 3% of total deaths worldwide

The discovery of carcinogens revealed the pathogenesis of NSCLC

Although the development of corresponding kinase inhibitors has improved treatment strategies and improved patient survival rates, targeted therapies for most patients with advanced NSCLC have not yet been developed because the tumors of these patients lack known carcinogens

On November 24, in a new study published in Nature, researchers from the National Cancer Center of Japan used the team’s self-developed lung cancer genome screening platform (LC-SCRUM-Asia) to screen for potential lung cancer carcinogens through a series of studies After verification, they found that CLIP1-LTK is a new target for the treatment of NSCLC.

First, the researchers performed Whole Transcriptome Sequencing (WTS) on samples of NSCLC cases whose oncogenes were not found in the LC-SCRUM-Asia screening , and found the CLIP1-LTK oncogene fusion in one of the positive samples

Next, the researchers demonstrated that CLIP1-LTK protein can form dimers (ie protein dimerization), thereby activating CLIP1-LTK kinase

Thanks to the above results, looking for kinase inhibitors of CLIP1-LTK protein will have clinical therapeutic significance

Finally, a NSCLC patient with CLIP1-LTK received lorlatinib treatment.

In summary, this study reported for the first time the relationship between LTK mutations and carcinogenic activity, confirming that CLIP1-LTK is a new target for NSCLC, and lorlatinib can be used to treat currently untreated NSCLC patients

references:

1Hiroki Izumi, Shingo Matsumoto, Jie Liu, et al.